Oxagen Limited

Atopix Therapeutics Limited

Eric Roy Pettipher

Mark Whittaker

Frederick Arthur Brookfield

Edward Andrew Boyd

Graham Michael Wynne

Richard Edward Armer

Mark Richard Ashton

Julia Vile

Frank Schroer

David Middlemiss

Michael George Hunter

Chris Palmer

Christopher Palmer

Mick Hunter

Compounds of general formula (II) wherein

Compounds having CRTH2 antagonist activity

Compounds of general formula (I) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

The present invention provides indole derivatives that antagonize prostaglandin D, and that can be used to treat inflammatory diseases mediated by prostaglandin D.

Treatment of CRTH2-mediated diseases and conditions

Compounds of general formula (II) whereinW is chloro or fluoro;Ris phenyl optionally substituted with one or more substituents, selected from halo, &#x2014;CN, &#x2014;C-Calkyl, &#x2014;SOR, &#x2014;SOR, &#x2014;SON(R), &#x2014;N(R), &#x2014;NRC(O)R, &#x2014;COR, &#x2014;CONRR, &#x2014;NO, &#x2014;OR, &#x2014;SR, &#x2014;O(CH)OR, or &#x2014;O(CH)O(CH)ORwherein

Compounds for the treatment of CRTH2-mediated diseases and conditions

Growing community of inventors

Oxon, United Kingdom

Eric Roy Pettipher